Showing results (81-90 of 753) with videos related to
Sort By:
Pageof 76
Japanese Journal of Infectious Diseases|October 28, 2004
The role of myeloperoxidase in the pathogenesis of coronary artery diseaseStephen J Nicholls, Stanley L HazenExpert Review of Cardiovascular Therapy|December 25, 2008
Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitusJohn M Galla, Stephen J NichollsVascular Health and Risk Management|April 8, 2015
Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Daniel J Scherer, Stephen J NichollsTherapeutics and Clinical Risk Management|April 28, 2010
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemiaAyman A Hussein, Stephen J NichollsJournal of Lipid Research|December 19, 2008
Myeloperoxidase, modified lipoproteins, and atherogenesisStephen J Nicholls, Stanley L HazenAmerican Journal of Preventive Cardiology|July 20, 2022
Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imagingGiuseppe Di Giovanni, Stephen J NichollsCleveland Clinic Journal of Medicine|December 28, 2017
Results of the GLAGOV trialSteven E Nissen, Stephen J NichollsArteriosclerosis, Thrombosis, and Vascular Biology|March 26, 2005
Myeloperoxidase and cardiovascular diseaseStephen J Nicholls, Stanley L HazenCurrent Cardiology Reports|July 1, 2021
The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?Stephen J Nicholls, Kristen J BubbCurrent Opinion in Lipidology|July 11, 2007
New targets of high-density lipoprotein therapyStephen J Nicholls, Steven E NissenPageof 76